The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies

Citations Over TimeTop 1% of 2021 papers

Abstract

Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that affects patients' function, quality of life, and ability to tolerate treatment. In certain patients with cancer, OM is associated with increased mortality. Research on the management of OM is ongoing. Oral mucosal toxicities are also reported in targeted and immune checkpoint inhibitor therapies. The objective of this article is to present current knowledge about the epidemiology, pathogenesis, assessment, risk prediction, and current and developing intervention strategies for OM and other ulcerative mucosal toxicities caused by both conventional and evolving forms of cancer therapy.

Related Papers

• → Effectiveness of honey on radiation-induced oral mucositis, time to mucositis, weight loss, and treatment interruptions among patients with head and neck malignancies: A meta-analysis and systematic review of literature(2016)52 cited
• → Oral mucositis in patients receiving reduced-intensity regimens for allogeneic hematopoietic cell transplantation: comparison with conventional regimen(2009)26 cited
• → Evaluation of oral mucositis in oral cancer patients undergoing radiotherapy(2018)3 cited
• → Acute Oral Mucositis During Hypo-Fractionated Radiation in Squamous Cell Carcinoma of Oral Cavity(2023)1 cited
• [Management of oral mucositis in patients with head and neck cancer receiving chemoradiotherapy and/or molecular targeted therapy].(2011)